CLINICAL STUDY PROTOCOL

A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe and at Risk of Fracture This study will be conducted according to the protocol and in compliance with Good Clinical Practice, the ethical principles stated in the Declaration of Helsinki, and other applicable regulatory requirements.

Protocol Number: Protocol BA058-05-003 EudraCT Number: 2010-022576-30 IND Number: 73,176 Protocol Date (Version): 2 December 2010 (Version 1.0) 21 October 2011 (Version 2.0) 17 November 2011 (Version 2.0) 5 July 2012 (Version 3.0) 31 March 2014 (Version 4.0) Study Sponsor: Radius Health, Inc. (RADIUS) 201 Broadway, 6th Floor Cambridge, MA 02139, USA Tel: 617.551.4700 Fax: 617.551.4701 Sponsor Medical Monitor/Study Alan Harris, MD Safety Officer Executive Medical Officer, Radius Health, Inc. Tel: 617.599.3780. Fax: 617.551.4701. Email: [email protected]

Contract Research Organization Nordic Bioscience A/S (CRO): Herlev Hovedgade 207 2730 Herlev, Denmark Tel: +45 4452 5252. Fax: +45 4452 5251 Study Site: Multicenter; international

Disclosure Statement This document contains information that is confidential and proprietary to Radius Health, Incorporated (RADIUS). This information is being provided to you solely for the purpose of evaluation and/or conducting a clinical trial for RADIUS. You may disclose the contents of this document only to study personnel under your supervision and/or to your institutional review board(s) or ethics committee(s) who need to know the contents for this purpose and who have been advised on the confidential nature of the document.

Downloaded From: https://jamanetwork.com/ on 09/28/2021 Radius Health, Inc. Confidential

PROTOCOL SYNOPSIS Title: A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of Fracture Protocol Number: BA058-05-003 Phase:3 Test Drug: Abaloparatide-SC Study Objectives: Please note that the name of BA058 Injection 80 μg has been changed to Abaloparatide-SC, therefore, the name has been changed throughout the document.

The primary objective of this study is to determine the safety and efficacy of Abaloparatide-SC when compared to a matching Placebo for prevention of vertebral fracture in otherwise healthy ambulatory postmenopausal women at risk of fracture from severe osteoporosis. Patients, investigators and independent assessors will be blinded as to treatment for that outcome. The secondary outcomes, also double-blind, of this study are to determine the safety and efficacy of Abaloparatide-SC when compared to Placebo for prevention of non-vertebral fractures and for change in vertical height. Additional key secondary efficacy outcomes include bone mineral density of spine, hip and femoral neck and hypercalcemia when compared to (Forteo®/Forsteo®, Eli Lilly and Co.), which will be assessor-blind. The specific objectives of this study are to: x Determine the comparative efficacy of 18 months of treatment with Abaloparatide-SC on reduction of vertebral fracture incidence in otherwise healthy ambulatory postmenopausal women at risk of fracture from severe osteoporosis when compared with Placebo. x Determine the comparative efficacy of 18 months of treatment with Abaloparatide-SC on lumbar spine, hip, and femoral neck bone mineral density (BMD) in otherwise healthy ambulatory postmenopausal women with severe osteoporosis when compared to teriparatide. x Determine the comparative efficacy of 18 months of treatment with Abaloparatide-SC on reduction of non-vertebral fracture incidence in otherwise healthy ambulatory postmenopausal women at risk of fracture fro